The estimated Net Worth of Willis C Lee is at least $243 Thousand dollars as of 26 February 2024. Mr Lee owns over 115,200 units of Emmaus Life Sciences Incorporation stock worth over $3,188 and over the last 5 years he sold EMMA stock worth over $0. In addition, he makes $240,000 as Vice Chairman & COO at Emmaus Life Sciences Incorporation.
Sign up
Mr S EMMA stock SEC Form 4 insiders trading
Mr has made over 31 trades of the Emmaus Life Sciences Incorporation stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 115,200 units of EMMA stock worth $14,976 on 26 February 2024.
The largest trade he's ever made was buying 115,200 units of Emmaus Life Sciences Incorporation stock on 26 February 2024 worth over $14,976. On average, Mr trades about 12,993 units every 50 days since 2019. As of 26 February 2024 he still owns at least 159,400 units of Emmaus Life Sciences Incorporation stock.
You can see the complete history of Mr Lee stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Willis C. Lee M.S. biography
Willis C. Lee M.S. is the Vice Chairman & COO at Emmaus Life Sciences Incorporation.
What is the salary of Mr S?
As the Vice Chairman & COO of Emmaus Life Sciences Incorporation, the total compensation of Mr S at Emmaus Life Sciences Incorporation is $240,000. There are 1 executives at Emmaus Life Sciences Incorporation getting paid more, with Dr. Yutaka Niihara M.D., M.P.H, M.P.H. having the highest compensation of $385,000.
How old is Mr S?
Mr S is 61, he's been the Vice Chairman & COO of Emmaus Life Sciences Incorporation since . There are 6 older and 6 younger executives at Emmaus Life Sciences Incorporation. The oldest executive at Emmaus Life Sciences Incorporation is Ian Zwicker, 71, who is the Director.
What's Mr S's mailing address?
Willis's mailing address filed with the SEC is 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE, CA, 90503.
Insiders trading at Emmaus Life Sciences Incorporation
Over the last 5 years, insiders at Emmaus Life Sciences Incorporation have traded over $1,625 worth of Emmaus Life Sciences Incorporation stock and bought 2,618,727 units worth $3,075,792 . The most active insiders traders include Yutaka Niihara, Willis C Lee, and Seah H. Lim. On average, Emmaus Life Sciences Incorporation executives and independent directors trade stock every 10 days with the average trade being worth of $325. The most recent stock trade was executed by Willis C Lee on 26 February 2024, trading 115,200 units of EMMA stock currently worth $14,976.
What does Emmaus Life Sciences Incorporation do?
emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.
What does Emmaus Life Sciences Incorporation's logo look like?
Complete history of Mr Lee stock trades at Emmaus Life Sciences Incorporation
Emmaus Life Sciences Incorporation executives and stock owners
Emmaus Life Sciences Incorporation executives and other stock owners filed with the SEC include:
-
Dr. Yutaka Niihara M.D., M.P.H, M.P.H.,
Chairman & CEO -
Yasushi Nagasaki CPA, CPA,
Chief Financial Officer -
Willis C. Lee M.S.,
Vice Chairman & COO -
Ian Zwicker,
Director -
Wei Peu Zen,
Director -
Jane Wood,
Director -
Masaharu Osato,
Director -
Robert Dickey,
Director -
Yasushi Nagasaki,
Interim Chief Financial Officer -
Willis Lee,
Vice Chairman of the Board, Chief Operating Officer -
Lan Tran,
President, Chief Administrative Officer -
Yutaka Niihara,
Chairman of the Board, Chief Executive Officer -
S. Steven Lee,
Independent Consultant -
Kurt H. Kruger M.B.A., M.S.,
Consultant -
Dr. Charles W. Stark Pharm.D., Pharm.D,
Sr. VP of Medical Affairs, Clinical, Regulatory -
Dale E. Short J.D.,
Gen. Counsel -
George Sekulich,
Sr. VP of Global Commercialization & Chief Information Officer -
Charles William Stark,
CSO & EVP Clinical Development -
Seah H. Lim,
Director -
Alfred Fu Kong Lui,
Director -
George Sekulich,
Co-President & CCO